| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A challenging drug development process in the era of personalized medicine
|
Jørgensen, Jan Trøst
|
|
2011
|
16 |
19-20 |
p. 891-897
7 p.
|
artikel
|
| 2 |
A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics
|
Wu, Rongling
|
|
2011
|
16 |
19-20 |
p. 884-890
7 p.
|
artikel
|
| 3 |
Considerations for safety pharmacogenetics in clinical practice
|
Frueh, Felix W.
|
|
2011
|
16 |
19-20 |
p. 898-901
4 p.
|
artikel
|
| 4 |
Contents
|
|
|
2011
|
16 |
19-20 |
p. iii-
1 p.
|
artikel
|
| 5 |
Contents
|
|
|
2011
|
16 |
19-20 |
p. v-
1 p.
|
artikel
|
| 6 |
Drug–diagnostic co-development: how to harness the value
|
Blair, Edward D.
|
|
2011
|
16 |
19-20 |
p. 902-905
4 p.
|
artikel
|
| 7 |
European attitudes to gene therapy and pharmacogenetics
|
Hudson, John
|
|
2011
|
16 |
19-20 |
p. 843-847
5 p.
|
artikel
|
| 8 |
Pharmacogenetics and cost-effectiveness analysis: a two-way street
|
Chalkidou, Kalipso
|
|
2011
|
16 |
19-20 |
p. 873-877
5 p.
|
artikel
|
| 9 |
Pharmacogenetics: past, present and future
|
Pirmohamed, Munir
|
|
2011
|
16 |
19-20 |
p. 852-861
10 p.
|
artikel
|
| 10 |
Pharmacogenetics: practices and opportunities for study design and data analysis
|
Flynn, Aiden A.
|
|
2011
|
16 |
19-20 |
p. 862-866
5 p.
|
artikel
|
| 11 |
Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives
|
Prasad, Krishna
|
|
2011
|
16 |
19-20 |
p. 867-872
6 p.
|
artikel
|
| 12 |
Stratified medicine: making it happen
|
Foot, Elizabeth
|
|
2011
|
16 |
19-20 |
p. 848-849
2 p.
|
artikel
|
| 13 |
The biomarker is not the end
|
Nohaile, Michael
|
|
2011
|
16 |
19-20 |
p. 878-883
6 p.
|
artikel
|
| 14 |
The impact of genetic biomarkers on drug and companion diagnostic return on investment
|
Keeling, Peter
|
|
2011
|
16 |
19-20 |
p. 850-851
2 p.
|
artikel
|
Tijdschrift beschrijving